FADD and prostate carcinoma: Since we previously demonstrated activation of JNK and phosphorylation of FADD by paclitaxel in prostate cancer cells (Shimada et al, 2004), we examined the cytotoxicity of paclitaxel for long-term tamoxifen treatment, in MDA-MB-231.